Review of the use of hepatitis B core antibody-positive kidney donors

Transplantation Reviews

Volumn 24, Issue 4, 2010, Pages 167-171

  Ouseph, Rosemary ^a,b   Eng, Mary ^a,b   Ravindra, Kadiyala ^c   Brock, Guy N ^d   Buell, Joseph F ^e   Marvin, Michael R ^a,b  

^a JEWISH HOSPITAL   (United States)

^b University of Louisville School of Medicine   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBINTERFERON ALPHA2B; ANTIVIRUS AGENT; AS 04; ASPARTATE AMINOTRANSFERASE; BASILIXIMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B CORE ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; OKT 3; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VIRUS DNA;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOPROPHYLAXIS; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; REVIEW; SEROCONVERSION; SURGICAL RISK; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 77957009383     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.05.001     Document Type: Review

References (35)

1. 2007 OPTN/SRTR annual report. http://www.ustransplant.org.
2. Scientific registry of transplant recipients 2008. Accessed July 29, 2009. http://www.ustransplant.org/.
3. Sokohl K. Reducing organ wastage: OAC analyzes use and discard data, suggests improvements Sept-Oct 2007. http://www.unos.org/SharedContentDocuments/Reducing_organ_wastage.
4. Grob P., Jilg W., Bornhak H., Gerken G., Gerlich W., Gunther S., et al. Serological pattern "Anti-HBC alone": report on a workshop. J Med Virol 2000, 62:450-455.
5. Aroldi A., Lampertico P., Montagnino G., Passerini P., Villa M., Campise M.R., et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005, 79:1132-1136.
6. Olsen S.K., Brown R.S. Hepatitis B treatment: lessons for the nephrologist. Kidney Int 2006, 70:1897-1904.
7. CDC Division of Viral Hepatitis-hepatitis B FAQs for health professionals http://www.cdc/gov/hepatitis/HBV.
8. Delmonico F.L. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 2000, 31:781-786.
9. OPTN/UOS Policy 4. http://www.unos.org/policiesandbylaws2/policies.
10. Ison M.G., Pruett T., Teperman L., Covington S., Taylor K., Blumberg K., et al. Donor serologic screening: current practices and future challenges-a survey reported by the OPTN/UNOS ad hoc Diseases Transmission Advisory Committee (DTAC) 2009.
11. Wolf J.L., Perkins H.A., Schreeder M.T., Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979, 91:412-413.
12. Wei H.K., Loong C.C., King K.L., Wu C.W., Lui W.Y. HBsAg(+) donor as a kidney transplantation deceased donor. Transplant Proc 2008, 40:2097-2099.
13. Sumethkul V., Ingsathit A., Jirasiritham S. Ten-year follow-up of kidney transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 2009, 41:213-215.
14. Berber I., Aydin C., Yigit B., Turkmen F., Titiz I.M., Altaca G. The effect of HBSAg-positivity of kidney donors on long-term patient and graft outcome. Transplant Proc 2005, 37:4173-4175.
15. Natov S.N., Pereira B.J.G. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (part 1: hepatitis B virus). Transpl Infect Dis 2002, 4:117-123.
16. De Villa V.H., Chen Y.S., Chen C.L. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation 2003, 75:S49-S53.
17. Wachs M.E., Amend W.J., Asher N.L., Bretan P.N., Emond J., Lake J.R., et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995, 59:230-234.
18. Ling T.J., Hepatitis B. The virus and disease. Hepatology 2009, 49:S13-S21.
19. Challine D., Chevaliez S., Pawlotsky J.M. Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors. Gastroenterology 2008, 135:1185-1191.
20. Cirocco R., Zucker K., Contreras N., Olson L., Cravero J., Markou M., et al. The presence of hepatitis B core antibody does no preclude kidney donation: lack of viral DNA in the serum and biopsies of core antibody-positive donors and clinical follow-up. Transplantation 1997, 63:1702-1703.
21. Fong T.L., Bunnapradist S., Jordan S., Cho Y.W. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network of Organ Sharing Database between 1994-1999. Transplantation 2002, 73:85-89.
22. Satterthwaite R., Ozgu I., Shidban H., Aswad S., Sunga V., Zapanta R., et al. Risks of transplanting kidneys form hepatitis B surface antigen-negative, hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997, 64:432-435.
23. Maydag R.M., Johnson L.B., Bartlett S.T., Schweitzer E.J., Constantine N.T., McCarter R.J., et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997, 64:1781-1786.
24. Krieger N.R., Vial C.M., Millan M.T., Imperial J., Dafoe D.C., Schandling J.D. Revisiting the use of hepatitis B core antibody-positive donor kidneys. Trans Proc 2001, 33:1535-1536.
25. De Feo T.M., Poli F., Mozzi F., Moretti M.P., Scalamogna M. Risk of transmission of hepatitis B virus from anti-HBc positive cadaveric organ donors: a collaborative study. Trans Proc 2005, 37:1238-1239. Collaborative Kidney, Liver and Heart North Italy transplant program Study Groups.
26. Fytili P., Ciesek S., Manns M.P., Wedemeyer H., Neipp M., Helfritz F., et al. Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. Letters to the Editor. Transplantation 2006, 82:808-809.
27. Veroux M., Puliatti C., Gagliano M., Cappello D., Macarone M., Vizcarra D., et al. Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients. Trans Proc 2005, 37:2574-2575.
28. Akalin E., Ames S., Sehgal V., Murphy B., Bromberg J.S. Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant 2005, 19:364-366.
29. Avettabd-Fenoel V., Thabut D., Katlama C., Poynard T., Thibault V. Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol 2006, 6:2250-2253.
30. Appendix A. Immunization management issues. MMWR Recomm Rep 2006, 55(RR 16):26-29.
31. Chung R.T., Feng S., Delmonico F.L. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001, 1:185-191.
32. Singh N.P., Mandal S.K., Thakur A., Kapoor D., Anuradha S., Prakash A., et al. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure-results of a prospective, randomized trial. Ren Fail 2003, 25:255-266.
33. Miquilena-Colina M.E., Lozano-Rodriguez T., Garicia-Pozo L., Saez A., Rizza P., Capone I., et al. Recombinant interferon-2αb improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomized clinical trial. Vaccine 2009, 27:5654-5660.
34. Kong N.C.T., Beran J., Kee S.A., Miguel J.L., Sanchez C., Bayas J.M., et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008, 73:856-862.
35. Sorrell M.F., Belongia E.A., Costa J., Gareen I.F., Grem J.L., Inadomi J.M., et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009, 150:104-110.